Daptomycin: The role of high-dose and combination therapy for Gram-positive infections

International Journal of Antimicrobial Agents

Volumn 42, Issue 3, 2013, Pages 202-210

  Gould, Ian M ^a   Miró, José M ^b   Rybak, Michael J ^c  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Combination therapy; Daptomycin; High dose; MRSA; Staphylococcus aureus

Indexed keywords

COTRIMOXAZOLE; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; LINEZOLID; NAFCILLIN; OXACILLIN; RIFAMPICIN; VANCOMYCIN;

ANEMIA; ARTHRALGIA; BACTEREMIA; BACTERIAL ENDOCARDITIS; BLOODSTREAM INFECTION; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAM POSITIVE INFECTION; HUMAN; HYPOKALEMIA; KIDNEY FAILURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NAUSEA; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT OUTCOME;

COMBINATION THERAPY; DAPTOMYCIN; HIGH DOSE; MRSA; STAPHYLOCOCCUS AUREUS;

BACTEREMIA; DAPTOMYCIN; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS; HUMANS; OSTEOMYELITIS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84883451020     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.05.005     Document Type: Review

References (87)

1. ® (daptomycin) summary of product characteristics 2012 Novartis Europharm Ltd Basel, Switzerland
2. R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, and B.I. Eisenstein The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections Clin Infect Dis 38 2004 1673 1681
3. V.G. Fowler Jr., H.W. Boucher, G.R. Corey, E. Abrutyn, A.W. Karchmer, and M.E. Rupp Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus N Engl J Med 355 2006 653 665
4. S.R. Quist, G. Fierlbeck, R.A. Seaton, J. Loeffler, and R.L. Chaves Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections Int J Antimicrob Agents 39 2012 90 91
5. H.S. Sader, A.A. Watters, T.R. Fritsche, and R.N. Jones Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005) BMC Infect Dis 7 2007 29
6. S.N. Leonard, and M.J. Rybak Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations J Antimicrob Chemother 63 2009 155 160
7. L.D. Saravolatz, J. Pawlak, and L.B. Johnson In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates Clin Infect Dis 55 2012 582 586
8. A.D. Hall, M.E. Steed, C.A. Arias, B.E. Murray, and M.J. Rybak Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/ pharmacodynamic model with simulated endocardial vegetations Antimicrob Agents Chemother 56 2012 3174 3180
9. R. Cha, R.G. Grucz Jr., and M.J. Rybak Daptomycin dose-effect relationship against resistant Gram-positive organisms Antimicrob Agents Chemother 47 2003 1598 1603
10. A. Louie, P. Kaw, W. Liu, N. Jumbe, M.H. Miller, and G.L. Drusano Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection Antimicrob Agents Chemother 45 2001 845 851
11. Cubist Pharmaceuticals Inc. Cubicin (daptomycin) prescribing information 2012 Cubist Pharmaceuticals Inc Lexington, MA, USA
12. M. Benvenuto, D.P. Benziger, S. Yankelev, and G. Vigliani Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers Antimicrob Agents Chemother 50 2006 3245 3249
13. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, valid from 2012-01-01. EUCAST; 2012. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST- files/Breakpoint-tables/Breakpoint-table-v-2.0-120221.pdf [accessed 23.10.12].
14. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: twenty-first international supplement. Document M100-S21 2011 CLSI Wayne, PA
15. C.A. Arias, D. Panesso, D.M. McGrath, X. Qin, M.F. Mojica, and C. Miller Genetic basis for in vivo daptomycin resistance in enterococci N Engl J Med 365 2011 892 900
16. A. Fischer, S.J. Yang, A.S. Bayer, A.R. Vaezzadeh, S. Herzig, and L. Stenz Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach J Antimicrob Chemother 66 2011 1696 1711
17. A. Dhand, A.S. Bayer, J. Pogliano, S.J. Yang, M. Bolaris, and V. Nizet Use of antistaphylococcal β-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding Clin Infect Dis 53 2011 158 163
18. B.J. Werth, G. Sakoulas, W.E. Rose, J. Pogliano, R. Tewhey, and M.J. Rybak Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model Antimicrob Agents Chemother 57 2013 66 73
19. J.M. Miró, J.M. Entenza, A. del Río, M. Velasco, X. Castañeda, and C. Garcia de la Mària High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis Antimicrob Agents Chemother 56 2012 4511 4515
20. G. Sakoulas, A.S. Bayer, J. Pogliano, B.T. Tsuji, S.J. Yang, and N.N. Mishra Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium Antimicrob Agents Chemother 56 2012 838 844
21. S. Mehta, C. Singh, K.B. Plata, P.K. Chanda, A. Paul, and S. Riosa β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives Antimicrob Agents Chemother 56 2012 6192 6200
22. K.H. Rand, and H. Houck Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci J Antimicrob Chemother 53 2004 530 532
23. T.U. Furustrand, I. Majic, B.C. Zalila, B. Betrisey, S. Corvec, and W. Zimmerli Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model Antimicrob Agents Chemother 55 2011 4821 4827
24. K. Credito, G. Lin, and P.C. Appelbaum Activity of daptomycin alone and in combination with rifampicin and gentimicin against Staphylococcus aureus assessed by time-kill methodology Antimicrob Agents Chemother 51 2007 1504 1507
25. M.E. Steed, B.J. Werth, C.E. Ireland, and M.J. Rybak Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations Antimicrob Agents Chemother 56 2012 5709 5714
26. L.M. Avery, M.E. Steed, A.E. Woodruff, M. Hasan, and M.J. Rybak Daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole Antimicrob Agents Chemother 56 2012 5990 5993
27. A. Saleh-Mghir, C. Muller-Serieys, A. Dinh, L. Massias, and A.C. Cremieux Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 55 2011 4589 4593
28. C. Garrigos, O. Murillo, G. Euba, R. Verdaguer, F. Tubau, and C. Cabellos Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 54 2010 5251 5256
29. J. Parra-Ruiz, C. Vidaillac, W.E. Rose, and M.J. Rybak Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm Antimicrob Agents Chemother 54 2010 4329 4334
30. C. García-de-la-Mària, J.M. Pericas, A. del Río, X. Castañeda, X. Vila-Farrés, and Y. Armero Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group streptococci after exposure to daptomycin Antimicrob Agents Chemother 57 2013 2319 2325
31. G. Wu, T. Abraham, J. Rapp, F. Vastey, N. Saad, and E. Balmir Daptomycin: evaluation of a high-dose treatment strategy Int J Antimicrob Agents 38 2011 192 196
32. J.N. Steenbergen, J.F. Mohr, and G.M. Thorne Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies J Antimicrob Chemother 64 2009 1130 1138
33. H. Wisplinghoff, T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel, and M.B. Edmond Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 39 2004 309 317
34. D.J. Biedenbach, G.J. Moet, and R.N. Jones Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002) Diagn Microbiol Infect Dis 50 2004 59 69
35. C.K. Naber Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies Clin Infect Dis 48 Suppl. 2009 S231 S237
36. S.J. van Hal, D.L. Paterson, and I.B. Gosbell Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient - a review of the literature Eur J Clin Microbiol Infect Dis 30 2011 603 610
37. C. Liu, A. Bayer, S.E. Cosgrove, R.S. Daum, S.K. Fridkin, and R.J. Gorwitz Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis 52 2011 e18 e55
38. S.L. Davis, M.J. Rybak, J.A. Vazquez, E. Hershberger, P. Bernado, and D.P. Levine Comparison of high dose daptomycin (DAP) and dose optimized vancomycin (VAN) for MRSA bacteremia and infective endocarditis (IE) 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 9-12 September 2012; San Francisco, CA., Washington, DC: ASM Press 2012 Abstract L1-1638
39. K.P. Murray, J. Zhao, S.L. Davis, R. Kullar, K. Kaye, and P. Lephart Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study Clin Infect Dis 56 2013 1562 1569
40. M. Bassetti, E. Nicco, F. Ginocchio, F. Ansaldi, D. de Florentiis, and C. Viscoli High-dose daptomycin in documented Staphylococcus aureus infections Int J Antimicrob Agents 36 2010 459 461
41. R. Kullar, S.L. Davis, D.P. Levine, J.J. Zhao, C.W. Crank, and J. Segreti High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study Pharmacotherapy 31 2011 527 536
42. P.A. Moise, E. Hershberger, M.I. Amodio-Groton, and K.C. Lamp Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy Ann Pharmacother 43 2009 1211 1219
43. A.M. Casapao, R. Kullar, S.L. Davis, D.P. Levine, J.J. Zhao, and B.A. Potoski Daptomycin for treatment of enterococcal infections: multicenter, retrospective study 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 9-12 September 2012; San Francisco, CA., Washington, DC: ASM Press 2012 Poster K-275
44. P.A. Moise, M. Amodio-Groton, M. Rashid, K.C. Lamp, H.L. Hoffman-Roberts, and G. Sakoulas Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment Antimicrob Agents Chemother 57 2013 1192 1200
45. P. Moreillon, and Y.A. Que Infective endocarditis Lancet 363 2004 139 149
46. V.G. Fowler Jr., J.M. Miro, B. Hoen, C.H. Cabell, E. Abrutyn, and E. Rubinstein Staphylococcus aureus endocarditis: a consequence of medical progress JAMA 293 2005 3012 3021
47. V.H. Chu, J.M. Miro, B. Hoen, C.H. Cabell, P.A. Pappas, and P. Jones Coagulase-negative staphylococcal prosthetic valve endocarditis - a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study Heart 95 2009 570 576
48. A. del Río, I. Anguera, J.M. Miró, L. Mont, V.G. Fowler Jr., and M. Azqueta Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome Chest 124 2003 1451 1459
49. A. Ergin, O.K. Eser, and G. Hascelik Erythromycin and penicillin resistance mechanisms among viridans group streptococci isolated from blood cultures of adult patients with underlying diseases New Microbiol 34 2011 187 193
50. L.M. Baddour, W.R. Wilson, A.S. Bayer, V.G. Fowler Jr., A.F. Bolger, and M.E. Levison Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America Circulation 111 2005 e394 e434
51. G. Habib, B. Hoen, P. Tornos, F. Thuny, B. Prendergast, and I. Vilacosta Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the prevention, diagnosis, and treatment of infective endocarditis of the European Society of Cardiology (ESC) Eur Heart J 30 2009 2369 2413
52. W.E. Rose, S.N. Leonard, G. Sakoulas, G.W. Kaatz, M.J. Zervos, and A. Sheth Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations Antimicrob Agents Chemother 52 2008 831 836
53. W.E. Rose, M.J. Rybak, and G.W. Kaatz Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies J Antimicrob Chemother 60 2007 334 340
54. H.F. Chambers, L. Basuino, B. Diep, J. Steenbergen, S. Zhang, and P. Tattevin Relationship between susceptibility to daptomycin in vitro and activity in vivo in the rabbit model of aortic valve endocarditis Antimicrob Agents Chemother 53 2009 1463 1467
55. F. Caron, M.D. Kitzis, L. Gutmann, A.C. Cremieux, B. Maziere, and J.M. Vallois Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium Antimicrob Agents Chemother 36 1992 2611 2616
56. C. Tascini, A. Di Paolo, R. Poletti, S. Flammini, M. Emdin, and I. Ciullo Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis Antimicrob Agents Chemother 57 2013 601 602
57. L.Y. Chen, C.H. Huang, S.C. Kuo, C.Y. Hsiao, M.L. Lin, and F.D. Wang High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report BMC Infect Dis 11 2011 152
58. M. Lichterfeld, M.J. Ferraro, and B.T. Davis High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides Int J Antimicrob Agents 35 2010 96
59. C. García-de-la-Mària, F. Marco, Y. Armero, D. Soy, A. Moreno, and A. del Río Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide- intermediate Staphylococcus epidermidis Antimicrob Agents Chemother 54 2010 2781 2786
60. E. Durante-Mangoni, R. Casillo, M. Bernardo, C. Caianiello, I. Mattucci, and D. Pinto High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis Clin Infect Dis 54 2012 347 354
61. M. Rybak, B. Lomaestro, J.C. Rotschafer, R. Moellering Jr., W. Craig, and M. Billeter Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 2009 82 98
62. A.C. Schutt, and N.M. Bohm Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin Ann Pharmacother 43 2009 2108 2112
63. J.A. Mohamed, and D.B. Huang Biofilm formation by enterococci J Med Microbiol 56 2007 1581 1588
64. E. Lautenbach, L.A. LaRosa, A.M. Marr, I. Nachamkin, W.B. Bilker, and N.O. Fishman Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins Clin Infect Dis 36 2003 440 446
65. ® Outcomes Registry and Experience (EU-CORESM) 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 7-10 May 2011; Milan, Italy. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases 2011 Abstract P1538
66. M.J. DiNubile, and B.A. Lipsky Complicated infections of skin and skin structures: when the infection is more than skin deep J Antimicrob Chemother 53 Suppl. 2004 ii37 ii50
67. T.C. Jenkins, A.L. Sabel, E.E. Sarcone, C.S. Price, P.S. Mehler, and W.J. Burman Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship Clin Infect Dis 51 2010 895 903
68. S. Esposito, S. Noviello, S. Leone, A. Tice, G. Seibold, and D. Nathwani Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison Int J Antimicrob Agents 24 2004 473 478
69. R.A. Seaton Daptomycin: rationale and role in the management of skin and soft tissue infections J Antimicrob Chemother 62 Suppl. 2008 iii15 iii23
70. D.E. Katz, K.C. Lindfield, J.N. Steenbergen, D.P. Benziger, K.J. Blackerby, and A.G. Knapp A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria Int J Clin Pract 62 2008 1455 1464
71. D.P. Lew, and F.A. Waldvogel Osteomyelitis Lancet 364 2004 369 379
72. A.K. John, D. Baldoni, M. Haschke, K. Rentsch, P. Schaerli, and W. Zimmerli Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: the importance of combination with rifampin Antimicrob Agents Chemother 53 2009 2719 2724
73. C. Garrigos, O. Murillo, J. Lora-Tamayo, R. Verdaguer, F. Tubau, and C. Cabellos Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 57 2013 606 610
74. J. Parra-Ruiz, A. Bravo-Molina, A. Peña-Monje, and J. Hernández-Quero Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm J Antimicrob Chemother 67 2012 2682 2685
75. O. Murillo, C. Garrigos, M.E. Pachon, G. Euba, R. Verdaguer, and C. Cabellos Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 53 2009 4252 4257
76. J.A. Crompton, D.S. North, S.A. McConnell, and K.C. Lamp Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry J Chemother 21 2009 414 420
77. R.A. Seaton, K.N. Malizos, P. Viale, P. Gargalianos-Kakolyris, T. Santantonio, and E. Petrelli Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORESM database J Antimicrob Chemother 2013 10.1093/jac/dkt067 [Epub ahead of print]
78. P.S. Corona Pérez-Cardona, V. Barro Ojeda, D. Rodriguez Pardo, C. Pigrau Serrallach, E. Guerra Farfán, and C. Amat Mateu Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections J Antimicrob Chemother 67 2012 1749 1754
79. M. Bassetti, E. Nicco, E. Delfino, C. Fanciulli, and C. Viscoli Efficacy and safety of high-dose daptomycin in Staphylococcus aureus infections 20th European Congress of Clinical Microbiology and Infectious Diseases 10-13 April 2010; Vienna, Austria. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases 2010 S343 Poster 1229
80. B.H. Dvorchik, D. Brazier, M.F. DeBruin, and R.D. Arbeit Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects Antimicrob Agents Chemother 47 2003 1318 1323
81. F.B. Oleson Jr., C.L. Berman, J.B. Kirkpatrick, K.S. Regan, J.J. Lai, and F.P. Tally Once-daily dosing in dogs optimizes daptomycin safety Antimicrob Agents Chemother 44 2000 2948 2953
82. F.P. Tally, and M.F. DeBruin Development of daptomycin for Gram-positive infections J Antimicrob Chemother 46 2000 523 526
83. S.M. Bhavnani, C.M. Rubino, P.G. Ambrose, and G.L. Drusano Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis Clin Infect Dis 50 2010 1568 1574
84. D.A. Figueroa, E. Mangini, M. Amodio-Groton, B. Vardianos, A. Melchert, and C. Fana Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program Clin Infect Dis 49 2009 177 180
85. J. Parra-Ruiz, C. Dueñas-Gutiérrez, C. Tomás- Jiménez, J.P. Linares-Palomino, J. Garrido-Gomez, and J. Hernández-Quero Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy Eur J Clin Microbiol Infect Dis 31 2012 1771 1774
86. V. Huang, and M.J. Rybak Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function J Antimicrob Chemother 57 2006 116 121
87. J.M. Butterfield, B.A. Mueller, N. Patel, K.E. Cardone, D.W. Grabe, and N.N. Salama Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis Antimicrob Agents Chemother 57 2013 864 872